Nasdaq Silo News Today

All animal subjects tolerated maximum dosing Once-per-day human intranasal dosing regimen determined for clinical evaluation SARASOTA, FL, Feb. 28, 2024...

Preclinical study shows SPC-14’s effectiveness against LH (luteinizing hormone) stress, helplessness, and anxiety. SARASOTA, FL, Jan. 24, 2024 (GLOBE...

Final validation report expected in first quarter 2024 ENGLEWOOD CLIFFS, NJ, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo”...

Silo Pharma, Inc. (NASDAQ:SILO – Get Free Report) was the recipient of a large drop in short interest in December. As of December 15th, there was short interest totalling 55,800 shares, a drop of 28.7% from the November 30th total of 78,300 shares. Approximately 2.2% of the shares of the stock are sold short. Based […]

Human tissue study assessed SPU-21’s efficiency, optimization, and binding affinity ENGLEWOOD CLIFFS, NJ, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Silo...

Silo Pharma (NASDAQ:SILO – Get Free Report) and MGO Global (NASDAQ:MGOL – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, risk, earnings, dividends, valuation, profitability and analyst recommendations. Insider & Institutional Ownership 3.2% of Silo […]

Pre-IND submission to FDA targeted for first quarter 2024 Silo partners with Kymanox for SPC-15 ENGLEWOOD CLIFFS, NJ, Sept. 20, 2023 ...

Laidlaw assumed coverage on shares of Silo Pharma (NASDAQ:SILO – Free Report) in a research report sent to investors on Monday, Marketbeat Ratings reports. The firm issued a buy rating and a $10.00 price objective on the stock. Silo Pharma Stock Down 0.4 % Shares of NASDAQ:SILO opened at $1.89 on Monday. Silo Pharma has […]

Equities research analysts at Laidlaw assumed coverage on shares of Silo Pharma (NASDAQ:SILO – Get Free Report) in a research note issued to investors on Monday, Marketbeat Ratings reports. The brokerage set a “buy” rating and a $10.00 price target on the stock. Laidlaw’s price objective indicates a potential upside of 407.61% from the stock’s […]

Silo Pharma, Inc. (NASDAQ:SILO – Get Free Report) was the recipient of a significant decrease in short interest in the month of June. As of June 30th, there was short interest totalling 32,900 shares, a decrease of 82.7% from the June 15th total of 190,500 shares. Currently, 1.3% of the shares of the company are […]